PA 83 FhCMBAlternative Names: PA83 FhCMB; Plant derived recombinant protective antigen anthrax vaccine; rPA anthrax vaccine
Latest Information Update: 24 May 2016
At a glance
- Originator iBio Inc
- Developer Fraunhofer USA Center for Molecular Biotechnology
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Anthrax